Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A large, uniquely simple, randomised study to assess much more reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment in early breast cancer.

Trial Profile

A large, uniquely simple, randomised study to assess much more reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment in early breast cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2018

At a glance

  • Drugs Tamoxifen (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms aTTom
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 Sep 2014 Accrual to date is 110% according to United Kingdom Clinical Research Network record.
    • 31 May 2012 Additional trial locations added as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top